An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Idelalisib (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 18 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 06 May 2016 Status changed from not yet recruiting to recruiting.
- 18 Apr 2016 New trial record